Author

P. Hwu

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1 Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Organism:human· 2 Organism:mouse· 2 Assay:proteomics· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

J. Chen· 3 shared C. Bernatchez· 2 shared C. Creasy· 2 shared D. Zhou· 2 shared J. Tong· 2 shared A. Amritkar· 1 shared A. Chaudhri· 1 shared A. Lazar· 1 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 23 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

J. Chen

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Metabolic plasticity of T-cell therapies: multi-omic profiling of interacting human tumor-infiltrating lymphocytes and autologous tumor adoptive cell therapy

M. Martinez-Paniagua, C. Haymaker, J. Robinson, M. Harel, C. Creasy, J. R. T. Adolacion, X. An, M. Fathi, A. Rezvan, M. Kumar, A. Amritkar, S. E. Woodman, R. N. Amaria, T. Geiger, P. Hwu, , N. Varadarajan

This study profiles the metabolic interactions between TILs and autologous tumor cells in ACT, finding that responder TILs are more efficient at fatty acid oxidation under starvation.

bioRxiv · Sep 28, 2022 · PreprintImmunology

Enhancer Reprogramming in Melanoma Immune Checkpoint Therapy Resistance

M. Maitituoheti, A. Shi, M. Tang, L.-L. Ho, C. Terranova, K. Galani, E. Keung, C. Creasy, M. Wu, J. Chen, N. Chen, A. Singh, A. Chaudhri, N. Anvar, G. Tarantino, , K. Rai

The paper identifies enhancer-based biomarkers of resistance to anti-PD-1 therapy in melanoma and suggests enhancer blockade combined with ICB as a potential strategy to improve treatment responses.

bioRxiv · Aug 31, 2022 · PreprintCancer Biology

An antibody drug conjugate targeting a GSTA glycosite-signature epitope of mucin1 expressed by non-small cell lung cancer

D. Pan, Y. Tang, J. Tong, C. Xie, J. Chen, C. Feng, P. Hwu, W. Huang, D. Zhou

This paper develops an anti-MUC1 antibody-drug conjugate targeting a GSTA glycosite-signature epitope, showing potent antitumoral efficacy and low toxicity in NSCLC models.

bioRxiv · Dec 22, 2019Pharmacology & Toxicology

Normal development and fertility of Fut1, Fut2, and Sec1 triple knockout mice

J. Chen, C. Zhang, Z. Su, F. L. Li, P. Hwu, Z. Wang, Y. Wang, Y. Li, J. Tong, C. Chen, D. Zhou

This study generates triple knockout mice lacking Fut1, Fut2, and Sec1 to deplete H antigen, finding normal development and fertility despite the absence of the antigen.

bioRxiv · Apr 21, 2019 · PreprintBiochemistry